⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ELVN News
Enliven Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
ELVN
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
prnewswire.com
ELVN
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
prnewswire.com
ELVN
Enliven Therapeutics to Present at Upcoming Investor Conferences
prnewswire.com
ELVN
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
prnewswire.com
ELVN
Form 8-K
sec.gov
ELVN
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
prnewswire.com
ELVN
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
prnewswire.com
ELVN
Form 8-K
sec.gov
ELVN
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
prnewswire.com
ELVN